FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL						
OMB Number:	3235-0287					
Estimated average burden						
hours per response:	0.5					

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person [*] Stonehouse Jon P			2. Issuer Name and Ticker or Trading Symbol BIOCRYST PHARMACEUTICALS INC [BCRX]		tionship of Reporting Persor all applicable) Director	on(s) to Issuer 10% Owner	
(Last)	(First)	(Middle)			Officer (give title below)	Other (specify below)	
4505 EMPEROR BLVD. SUITE 200		(3. Date of Earliest Transaction (Month/Day/Year) 12/19/2024		President & CEO		
			4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line)			
(Street) DURHAM	NC	27703			Form filed by One Reporting Person Form filed by More than One Reporting		
(City)	(State)	(Zip)			Person		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

	Non Derivative		4	-,	-p,	••• =••	,	•		
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)		5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(1150.4)
Common Stock	12/19/2024		A		362,100(1)	A	\$ <mark>0</mark>	1,463,119	D	
Common Stock	12/19/2024		F		14,010(2)	D	\$7.39	1,449,109	D	
Common Stock	12/20/2024		G ⁽³⁾		20,000	D	\$ <mark>0</mark>	1,429,109	D	
Common Stock	12/20/2024		G ⁽³⁾		10,000	А	\$0	30,000	Ι	By wife as co-trustee of the Caroline Stonehouse Irrevocable Trust
Common Stock	12/20/2024		G ⁽³⁾		10,000	A	\$0	30,000	I	By wife as co-trustee of the Samuel Stonehouse Irrevocable Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) 7. Title and Amount of Securities Underlying Derivative Security 8. Price of Derivative 1. Title of 3. Transaction 3A. Deemed 5. Number of 6. Date Exercisable and 9. Number of 10 11. Nature 2. Conversion or Exercise Price of Derivative Security Ownership Form: Derivative Security Execution Date, Transaction Code (Instr. Derivative Expiration Date (Month/Day/Year) derivative of Indirect Beneficial Date (Month/Day/Year) if any (Month/Day/Year) Security (Instr. 5) Securities Form: Direct (D) or Indirect (I) (Instr. 4) Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) (Instr. 3) Beneficially 8) Ownership Beneticiany Owned Following Reported Transaction(s) (Instr. 3 and 4) (Instr. 4) Amount (Instr. 4) or Number Date Expiration Code v (A) (D) Exercisable Date Title of Shares Emp Stock \$7.39 12/19/2024 750,250 12/19/2025(4) 12/19/2034 750,250 \$<mark>0</mark> 750,250 D Option Α Stock (Right to Buy)

Explanation of Responses:

1. Annual award of Restricted Stock Units which will vest 25% on each of the first, second, third and fourth anniversaries of the date of grant.

2. Represents shares withheld by the Issuer to satisfy required tax withholding obligations in connection with the vesting of previously granted Restricted Stock Units. This transaction does not represent a sale by the Reporting Person.

3. On December 20, 2024, the Reporting Person gifted 10,000 shares held directly by him to each of the Samuel Stonehouse Irrevocable Trust and the Caroline Stonehouse Irrevocable Trust.

4. Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant.

<u>/s/ Alane P. Barnes, by power of</u> <u>attorney</u> <u>12/23/2024</u> ** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.